Merck's new antimicrobial drug Rikobo is being launched on the market in China.

On May 12th, MSD announced that its new carbapenem/enzyme inhibitor combination drug, Recarb, has officially been launched in China for the treatment of infections caused by sensitive Gram-negative bacteria in patients aged 18 and above, including hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, complicated urinary tract infections with limited or no alternative treatments, and complicated intra-abdominal infections with limited or no alternative treatments. It is reported that the first batch of drugs has been packaged at MSD's factory in Hangzhou, China, marking the domestic debut of the product.